Sandoz blocked by UK court from seeking Xarelto profits

A High Court decision clarifies how cross-undertakings work in patent disputes, rejecting claims for exceptional remedies beyond compensation.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

In-house with Bayer: ‘Focus on quality early and stay close to inventors’

15 July 2025 After almost 30 years as head of IP at Bayer, Jörg Thomaier is to retire and is handing the baton to Dorian Immler. Speaking to Sarah Speight, the pair explain what makes a good IP strategy, why the UPC is largely “useless” without SPCs, and more.

Europe

‘Always new twists’: Bayer legal team on defending a $4bn drug

31 March 2025 With billions in revenue at stake, the pharma giant has a 27-country parallel litigation effort to protect its blockbuster blood thinner from generics. Marisa Woutersen finds Bayer’s outside litigation counsel ready for anything.

Generics

Bayer irks High Court judge over £130k costs in refusing to produce document

9 January 2024 Judge says Bayer racked up high costs ‘in pursuit of vague point of principle’ | Teva and others wanted presentation slides as part of patent invalidity suit.

More features

All eyes on Squires: What IP experts want from the new USPTO director

Crafting claim strategies in animal and human therapeutics

MSD scores second win in patent fight over Keytruda

Scientist jumps from Jones Day to expand rival’s biotech offering

AIPPI: Personalised medicine tests the limits in patent law

Ropes & Gray loses 21-attorney group to join rival on growth spree

How 'Boehringer' sets preliminary relief threshold for generics

‘Whose trademark law is AI based on exactly?’: Key questions from Marques

Sandoz blocked by UK court from seeking Xarelto profits

More on this story

Editor's picks

Editor's picks

More features